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Abstract. Voltage-gated Na+ channels (VGSCs) are highly 
expressed in several types of carcinomas including breast, pros-
tate and lung cancers as well as in mesothelioma and cervical 
cancers. Although the VGSCs activity is considered crucial 
for the potentiation of cancer cell migration and invasion, 
the mechanisms responsible for their functional expression 
and regulation in cancer cells remain unclear. In the present 
study, the role of the small GTPase RhoA in the regulation of 
expression and function of the Nav1.5 channel in the breast 
cancer cell lines MDA-MB 231 and MCF-7 was investigated. 
RhoA silencing significantly reduced both Nav1.5 channel 
expression and sodium current indicating that RhoA exerts a 
stimulatory effect on the synthesis of an active form of Nav1.5 
channel in cancer cells. The inhibition of Nav1.5 expression 
dramatically reduced both cell invasion and proliferation. In 
addition, a decrease of RhoA protein levels induced by Nav1.5 
silencing was observed. Altogether, these findings revealed: 
i) the key role of the small GTPase RhoA in upregulation of 
Nav1.5 channel expression and tumor aggressiveness, and 
ii) the existence of a positive feedback of Nav1.5 channels on 
RhoA protein levels.
Introduction
Breast cancer is the most commonly occurring cancer in 
women. Each year approximately one million of new cases 
occurred in the world, 25-40% of patients developing metas-
tasis and dying from cancer (1,2). Many problems remain 
in its clinical management which is generally related to the 
malignancy types and drug resistance mechanisms as well 
as metastasis development. Additional investigations to 
understand the physiopathology of breast cancer are urgently 
necessary to develop new therapies based on new targets 
involved in cancer cell invasion and proliferation.
In previous studies we have already demonstrated that the 
upregulation and activation of the small GTPase RhoA or RhoC 
contribute to cell invasion leading to breast cancer metastasis 
(3,4). RhoA signaling pathways are implicated in the activation 
of FAK, Akt/PI3K, p38MAPK and MLCK, which have been 
shown to be responsible for cytoskeleton actin reorganization, 
cell adhesion, motility, migration and invasion (5-9). In many 
types of cancers, RhoA appears to be overexpressed and/or 
constitutively activated (10,11), and considered to be a negative 
clinical prognosis marker (10,12,13).
Recently, it has been shown that the voltage-gated Na+ 
channels (VGSCs) could be an accelerating factor in malig-
nant cancers (14-17). VGSCs are membrane panning proteins 
expressed in a wide variety of excitable and non-excitable 
cells, as well as in many carcinomas including breast cancer 
(18,19). VGSCs mainly mediate rapid and transient Na+ influx 
into cells and are classically responsible for generation and 
propagation of action potential. In cancer cells, overexpres-
sion of VGSCs and/or their upregulation has been observed. 
In particular, the Nav1.5 channel type correlates with cancer 
cell invasion (20-22). Although it seems that the neonatal 
isoform of Nav1.5 channel may be a potential target for cancer 
therapy, so far the mechanisms regulating its expression and 
its functional activity in cancer cells have not been clarified. 
A previous report revealed that the expression of the neonatal 
isoform of Nav1.5 was regulated by protein kinase A (23).
In the present study, the Nav1.5 channel expression was 
analyzed in invasive (MDA-MB-231) or less (MCF-7) invasive 
breast cancer cell lines. Due to the importance of RhoA in 
signaling pathways in cancer cell invasion, the involvement of 
RhoA in the expression and regulation of Nav1.5 was investi-
gated using the real-time RT-PCR and the electrophysiological 
patch-clamp techniques.
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Materials and methods
Cell culture. MDA-MB-231 cells were grown in RPMI-1640 
medium with 10% fetal bovine serum (FBS) (Eurobio), 2 mM 
L-glutamine. MCF-7 cells were grown in H-DMEM medium 
with 10% FBS, 4 mM L-glutamine. Both cell lines were 
obtained from ECACC. All cultures contained 100 IU/ml 
penicillin and 100 µg/ml of streptomycin (Eurobio) and were 
incubated at 37˚C in a humidified 5% CO2 atmosphere.
siRNA transfection. Specific siRNAs directed against human 
RhoA or Nav1.5 was designed using the criteria established by 
Tuschl. Candidate sequences were compared with cDNA 
sequences and their specificity verified in the non-redundant 
human DNA database using a BLAST algorithm [accession 
through NCBI]. The RhoA siRNA selected was: sense 5'-GAC 
AUGCUUGCUCAUAGUC-3', antisense 5'-CUGUACGAACG 
AGUAUCAG-3' and the Nav1.5 siRNA selected was: sense 
5'-GGCACAUGAUGGACUUCUU-3', antisense 5'-CCGU 
GUACCUGAAGAA-3'. Eurogentec negative control siRNA 
was used as control. siRNAs (10 nM) were introduced into 
cells by INTERFERin™-mediated transfection (Ozyme). In 
patch-clamp experiments, siRNAs were labeled with tetra-
methyl-rhodamin, and only red cells detected under fluorescent 
microscope were selected for recording.
Cell proliferation and viability. Cells were seeded (6x103/
well) in 96-well plates in growth medium complemented 
with 5% FBS. Cell proliferation/viability was evaluated using 
a [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS, Promega) 
assay at 24, 48 and 72 h after transfection. Cells were incubated 
with MTS in culture medium at 37˚C for 2 h. Optical density 
was read at 490 nm using a PowerWavex spectrophotometer 
(Bio-Tek Instruments Inc.).
Cancer cell invasion. Cells were cultured for 24 h in serum-
free medium. Cells (7.5x104) were seeded in the insert coated 
with Matrigel. The lower chamber was filled with 0.75 ml 
of RPMI-1640 containing 10% FCS to induce chemotaxis. 
Twenty-four or 72 hours later, the non-migrated cells in the 
upper chamber were gently scraped away, and invasive cells 
were fixed with methanol, stained with 1% toluidine/1% borax 
solution, and counted with Mercator software (Explora Nova). 
The invasion by MDA-MB-231 was tested after tranfection 
with control, RhoA or Nav1.5 siRNAs.
Quantitative polymerase chain reaction (qPCR) assay (real-
time RT-PCR). The transfected cells were harvested and total 
RNA was prepared by SV total RNA isolation system kit 
(Promega). The purity of total RNA was checked by a ratio of 
A260/A280 (>1.9). Total RNA (50 ng) was used to synthesize 
cDNA in 20 µl reaction solution using iScript™ cDNA 
Synthesis kit (Bio-Rad). Then 2 µl of cDNA was used for 
qPCR assay in duplicates with SYBR Green gene expression 
assay method. The primers for RhoA (forward primer: 5'-CGC 
TTTTGGGTACATGGAGT-3', reverse primer: 5'-GAGCAGC 
TCTCGTAGCCATT-3'), Nav1.5 (forward primer: 5'-CGCCTA 
CGTGATGAGTGAGA-3', reverse primer: 5'-TAGGAGGG 
TGGGAAGGAAGT-3') and GAPDH (forward primer: 5'-TGC 
ACCACCAACTGCTTAGC-3', reverse primer: 5'-GGCATG 
GACTGTGGTCATGAG-3') were purchased from Eurogentec, 
Belgium. The qPCR was performed using Quantifast™ SYBR® 
Green PCR kit (Qiagen) by 10 min of initial denaturation and 
44 cycles of 15 sec at 95˚C, 60 sec at 60˚C in a Master Cycler 
System (Eppendorf). The ratio of interest, mRNA and GAPDH 
mRNA, was used for analyzing qPCR results.
Western blot analysis. For protein extractions, 2x106 cells 
were seeded into 75-cm2 flasks. Forty-eight hours after treat-
ment, proteins were extracted by RIPA buffer complemented 
with protease and phosphatase inhibitor cocktail, concentra-
tion of protein was measured by BCA Protein Assay kit 
(Pierce). Protein fractions were separated by SDS-PAGE, 
then transferred onto polyvinylidene difluoride membranes 
(Amersham) using a dry transfer system (Invitrogen). 
Membranes were blocked with skim milk, and probed using 
anti-RhoA (Santa Cruz) and anti-GAPDH (Sigma-Aldrich) 
primary antibodies. GAPDH is used as control protein and 
for protein normalization. The detection was done using a 
secondary peroxidase-conjugated antibody (Dako). After 
washing the bound antibody was detected with Immobilon 
western chemiluminescente HRP substrate (Millipore). Then 
chemiluminescent emission was captured on Kodak XAR 
film. Images were analyzed by ImageJ software.
Electrophysiology. Whole-cell currents of MDA-MB-231 
human breast cancer cells were recorded using a conven-
tional patch-clamp technique. Prior to each experiment, the 
growth medium was replaced with an external bath solution 
containing (in mM): NaCl 144, KCI 5.4, MgCl2 1, CaCl2 2.5, 
D-glucose 5.6, and HEPES 5, adjusted to pH 7.3 with 1 M 
NaOH. Soft glass patch pipettes of resistance of 5-7 MΩ were 
filled with a solution containing (in mM): NaCl 5, CsCl 145, 
MgCl2 2, CaCl2 1, HEPES 10 and EGTA 11, adjusted to 
pH 7.4 with 1 M CsOH, to block outward K+ currents. A 
holding potential of -100 mV was applied, unless indicated 
otherwise. Standard voltage-clamp protocols were used 
to study the electrophysiological properties of the voltage-
gated sodium channels on MDA-MB-231 cells. Whole-cell 
currents of isolated cells were recorded at room temperature 
(23-25˚C).
Data acquisition and analysis. All current signals were 
recorded with Axopatch 700B amplifier (Axon Instruments, 
Union City, CA, USA) in the voltage-clamp mode. Analogue 
signals were filtered at 3 kHz using a lowpass Bessel filter 
and series resistance was compensated by ~70%. Currents 
were corrected on-line for leak and residual capacitance 
transients by a P/4 protocol. Electrophysiological signals were 
sampled at 10 kHz and digitised using Digidata 1440A (Axon 
Instruments). Data acquisition and analysis of membrane 
currents were performed with pClamp 10.2 software (Axon 
Instruments) and/or Origin 8.0 (Origin Lab, Northampton, 
MA, USA). Values are given as mean ± SEM with n as the 
number of cells tested. Statistical analysis was performed 
using the Student's t-test with paired comparisons where it was 
relevant. When multiple comparisons were made, data were 
analyzed by a one-way ANOVA test, followed by Tukey test 
when significant differences were observed.
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Statistical analysis. The Dunnett test was used for quantita-
tive comparisons between treatments. All experiments were 
reproduced at least 3 times on different days unless specified 
otherwise.
Results
Silencing of RhoA reduces sodium current. Whole-cell patch 
clamp recordings were used to measure sodium current (INa) 
in MDA-MB-231 human breast cells. Only the cells with 
red signals indicating successful transfection were chosen 
(Fig. 1A). Small interference RNAs targeting RhoA (RhoA 
siRNAs) dramatically reduced INa evoked by depolarizing 
pulses to -20 mV from a holding potential of -100 mV. As 
shown in Fig. 1B and C, the peak current in RhoA siRNA- 
treated cells (1016.1±163.2 pA, n=20) was decreased by 50.5% 
(p<0.05) compared to the control cells (2054.7±380.5 pA, 
n=16).
In order to clarify whether the decrease of the peak 
current may result from changes in functional properties or 
the number of channels expressed on the cell membrane, the 
effect of RhoA siRNAs on the steady-state activation and inac-
tivation properties of INa was further investigated. A protocol 
of 20-msec depolarizing pulses from a holding potential 
of -100 mV to between -60 and 90 mV, with 5 mV steps at 
intervals of 5 sec, was used. As shown in Fig. 2A and B, the 
evoked sodium current families were markedly reduced after 
RhoA silencing. However, RhoA silencing did not signifi-
cantly modify (p<0.05) the steady-state activation property of 
sodium channels. In all treated and untreated cells (16 cells 
for each group), the half-activation potential was -35.7±1.7 and 
-35.9±1.0, respectively (Fig. 2C and G).
The effect of RhoA siRNAs on the voltage dependence 
of steady-state inactivation of sodium channels was studied 
by inducing INa using 1-sec conditioning pre-pulses ranging 
from -130 to -10 mV, in steps of 5 mV prior to a -20 mV test 
Figure 1. Effect of RhoA siRNAs on the current amplitudes of voltage-gated sodium channels on MDA-MB-231 human breast cancer cells. (A) Merged 
fluorescence microscope images of cells transfected with blank siRNAs (control) and siRNAs targeting RhoA (RhoA siRNA). Sodium current of cells with 
red signals indicating successful transfection was recorded by whole-cell patch clamp technique. (B) Typical traces of INa elicited by a depolarization potential 
of -20 mV on MDA-MB-231 cells before (control) and after (RhoA siRNA) interference with RhoA siRNAs. (C) Statistical analysis of the effect of small 
interference RNAs targeting RhoA on the amplitude of INa on MDA-MB-231 cells. *p<0.05 compared with the corresponding control.
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Figure 2. Effects of RhoA siRNAs on the kinetics of voltage-gated sodium channels on MDA-MB-231 human breast cancer cells. (A) Typical traces of the 
steady-state activation of INa before (control) and after (RhoA siRNA) interference with RhoA siRNAs. The cells were held at -100 mV and depolarized in 5 mV 
steps from -60 to 90 mV at intervals of 5 sec. (B) The voltage-dependent activation curves of INa before (○) and after (•) interference with RhoA siRNAs. The 
data were obtained from 16 cells for each group and were expressed as mean ± SEM. (C) Comparison of the plots of normalized conductance as a function of 
the command potential before (○) and after (•) interference with RhoA siRNAs. RhoA siRNAs did not induce changes in Nav voltage-dependence of activation. 
(D) Typical traces of the steady-state inactivation of INa on MDA-MB-231 cells before (control) and after (RhoA siRNA) interference with RhoA siRNAs. INa 
was elicited using 1-sec conditioning pre-pulses ranging from -130 to -10 mV, in steps of 5 mV prior to a -20 mV test pulse. (E) The steady-state inactivation 
curves of INa before (○) and after (•) interference with RhoA siRNAs. The data were obtained from 29 cells (13 cells for control and 16 cells for RhoA siRNAs) 
and were expressed as mean ± SEM. (F) Comparison of the plots of normalized conductance as a function of the command potential before (○) and after (•) 
interference with RhoA siRNAs. RhoA siRNAs did not induce changes in the steady-state inactivation of Nav. (G) Statistical analysis of the half-activation and 
half-inactivation potentials of Nav on MDA-MB-231 cells before and after interference with RhoA siRNAs.
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pulse. Typical current traces and curves illustrating the rela-
tionship between the peak current and the pre-pulse potential 
is illustrated in Fig. 2D and E. The steady-state inactivation 
curves were then fitted using the Boltzmann equation of INa/
INamax=1/ {1+exp [(Vm-Vm1/2)/k]} +A (Fig. 2F). In all treated 
(n=16) and untreated (n=13) cells, Vm 1/2 was -85.8±0.6 mV and 
-86.1±0.4 mV, respectively without any significant (p<0.05) 
changes (Fig. 2G).
Among the different subtypes of VGSCs expressed in 
MDA-MB-231 human breast cancer cells, the Nav1.5 channel 
is suggested to be the major functional sodium channel 
subtype expressed in these cells. To further investigate the 
expression level of Nav1.5 channels, whole-cell patch clamp 
recordings were performed in cells treated with the small 
interference RNAs targeting Nav1.5 channels. As shown in 
Fig. 3A, transfection of Nav1.5 siRNA strongly reduced the 
Na current. Compared to control (2054.7±380.5 pA, n=16), 
the peak current amplitude in transfected cells was reduced to 
288.0±53.5 pA (n=25) (Fig. 3B).
We also examined the steady-state activation property of 
sodium current after interference with Nav1.5 siRNA. Fig. 4A 
shows representative whole-cell current families recorded 
from control or Nav1.5 siRNA treated cells. As observed in 
Fig. 4B the mean I/V curves obtained from control (n=7) or 
treated (n=6) cells showed that silencing the Nav1.5 sodium 
channel subtype significantly reduced the sodium peak current 
elicited by each depolarizing pulse tested. Fig. 4C illustrates 
that the evoked currents were half-activated at -30.0±2.0 mV 
Figure 3. Effect of Nav1.5 siRNAs on the current amplitudes of voltage-gated sodium channels on MDA-MB-231 human breast cancer cells. (A) Typical traces 
of INa elicited by a depolarization potential of -20 mV on MDA-MB-231 cells before (control) and after interference with Nav1.5 siRNA. (B) Statistical analysis 
of the effects of small interference RNAs targeting Nav1.5, on the amplitude of INa on MDA-MB-231 cells. *p<0.05 compared with the corresponding control.
Figure 4. Effects of Nav1.5 siRNA on the kinetics of voltage-gated sodium channels on MDA-MB-231 human breast cancer cells. (A) Typical traces of the 
steady-state activation of INa on MDA-MB-231 cells before (control) and after interference with Nav1.5 siRNA. The cells were held at -100 mV and depolarized 
in 5 mV steps from -60 to 90 mV at intervals of 5 sec. (B) Voltage-dependent activation curves of INa before and after interference with Nav1.5 siRNA. The data 
were obtained from 6-7 cells for each group and were expressed as mean ± SEM. (C) Statistical analysis of the half-activation potential of Nav on MDA-MB-231 
cells before and after interference with Nav1.5 siRNA.
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after silencing Nav1.5 channels without any significant differ-
ence (p>0.05) compared to the control (-35.7±1.7 mV).
Inhibition of RhoA expression downregulates Nav1.5 channels 
at transcription level. To further investigate the regulation 
mechanisms of RhoA on Nav1.5 channels, we compared the 
expression level of the channel molecules in the presence of 
RhoA or after RhoA silencing. In the present set of experi-
ments, the small interference RNA anti-RhoA or anti-Nav1.5 
were used in both aggressive MDA-MB-231 and less aggres-
Figure 5. Quantitative detection of RhoA and Nav1.5 expression. (A and B) The effect of RhoA or Nav1.5 siRNAs on RhoA transcription analyzed by real-time 
RT-PCR (mean ± SEM, MDA-MB-231: n=7; MCF-7: n=5; ***p<0.001; ****p<0.0001). (C and D) The effect of RhoA or Nav1.5 siRNAs on Nav1.5 expression. 
GAPDH expression level was used to control the mRNA concentration used in the experiments (mean ± SEM, MDA-MB-231: n=4; MCF-7: n=3; *p<0.05, 
***p<0.001, ****p<0.0001). (E and F) Western blot analysis of RhoA protein level in MDA-MB-231 (mean ± SEM, n=4; **p<0.01, ****p<0.0001) and MCF-7 
(mean ± SEM, n=2) cells, respectively at 48 h after treatment with RhoA or Nav1.5 siRNAs. The protein concentration of each band was analyzed by imageJ 
software and are presented as histograms.
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sive MCF-7 breast cancer cells. Real-time RT-PCR was 
applied to evaluate the transcriptional level of RhoA or Nav1.5 
expression. The histograms of Fig. 5A and B revealed that 
siRNA anti-RhoA markedly and significantly inhibited RhoA 
expression in both types of tumor cells (MDA-MB-231 cells: 
p<0.001, n=7; MCF-7 cells: p<0.0001, n=5) while siRNA anti-
Nav1.5 had no effect on RhoA transcriptional level. In contrast, 
interestingly, as observed in Fig. 5C and D, after siRNA anti-
RhoA treatment, the transcriptional level of Nav1.5 channels 
appeared to be significantly decreased (MDA-MB-231 cells: 
p<0.001, n=4; MCF-7 cells: p<0.05, n=3) with a similar range 
of inhibition in both types of breast cancer cells. It has to be 
noted that the inhibition level of Nav1.5 expression by siRNA 
anti-Nav1.5 was stronger in MDA-MB-231 than in MCF-7 
cells.
Inhibition of Nav1.5 expression downregulates the RhoA 
protein level. We investigated a potent effect of Nav1.5 chan-
nels on RhoA expression. Nav1.5 silencing did not modify 
the transcriptional level of RhoA (Fig. 5A and B) while it 
decreased its protein level in both aggressive (MDA-MB-231) 
and less aggressive (MCF-7) cells (Fig. 5E and F). The western 
blots shown in Fig. 5 clearly revealed that after a 48-h transfec-
tion, siRNA anti-Nav1.5 reduced by >50% the RhoA protein 
level (MDA-MB-231 cells: p<0.01, n=4; MCF-7 cells: n=2).
siRNA anti-Nav1.5 inhibits cell proliferation of MDA-MB-231 
but not of MCF-7. Additional experiments were conducted on 
cell proliferation. Results illustrated in Fig. 5A and B indicated 
that only siRNA anti-Nav1.5 inhibited cell proliferation in 
MDA-MB-231 cell line (p<0.0001; n=7 after 72-h treatment) 
while RhoA silencing failed to exert any effect. In contrast, in 
MCF-7 cells no significant effect was detected after treatment 
with siRNA anti-RhoA or anti-Nav1.5 (n=8).
RhoA and Nav1.5 promote tumor cell invasion. In order to 
establish the relationship between RhoA or Nav1.5 and tumor 
cell invasion, Boyden chamber assays were performed on 
MDA-MB-231 cells (MCF-7 cells have no invasive activity 
in this condition) after treatments with siRNA anti-RhoA or 
anti-Nav1.5. As shown in Fig. 6C, each siRNA tested signifi-
cantly (p<0.0001, n=6 after 48-h treatment; p<0.001, n=4 
after 72 h) inhibited cell invasion. It was noted that the RhoA 
silencing appeared to have a more pronounced effect than that 
of Nav1.5.
Discussion
In previous studies, it was suggested that the upregulation 
and activation of the small GTPase RhoA contribute to cell 
invasion leading to metastasis (10,13). Numerous data have 
elucidated that high RhoA expression and activation levels 
may be a negative prognostic marker in cancer treatment 
(10,12,13). We have also demonstrated that in the aggressive 
breast cancer cells, the proliferation and invasiveness were 
considerably reduced when the small GTPase RhoA was 
inhibited (24,25). Thus, we have developed a strategy of 
molecular therapy using anti-RhoA siRNAs. The efficacy of 
i.v.-administered encapsulated anti-RhoA siRNA in chitosan-
coated polyiso-hexylcyanoacrylate (PIHCA) nanoparticles 
in xenografted aggressive breast cancer MDA-MB-231 was 
demonstrated (3,4).
Figure 6. Tumor cell proliferation and invasion analysis. (A and B) Evaluation of cell proliferation after the siRNAs treatment of MDA-MB-231 (mean ± SEM, 
n=7; ****p<0.0001) and MCF-7 (mean ± SEM, n=8) cells. Cells were treated with 10 nM siRNAs (control or RhoA or Nav1.5). Cell survival was detected by 
MTS assay after 24, 48 and 72 h of treatment. (C) Evaluation of RhoA or Nav1.5 siRNAs on MDA-MB-231 cell invasion in Boyden chamber system. The 
number of invaded cells was counted 48 h (mean ± SEM, n=6; ***p<0.001, ****p<0.0001) and 72 h (mean ± SEM, n=4) after each treatment. 
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To understand the physiopathology of breast cancer, other 
reports suggested that upregulation of voltage-gated Na+ chan-
nels could be an accelerating factor in metastatic disease (26). 
The Na channel expression level appeared to be closely linked 
to the metastatic development in human breast cancer (19). 
As MDA-MB-231 cells are known to highly express Nav1.5 
channels on the cytoplasmic membrane, we investigated the 
relationship between the expression of RhoA and that of Na 
channels, particularly the Nav1.5 channels.
The present study was carried out on both invasive 
(MDA-MB-231) and less-invasive (MCF-7) cells. The expres-
sion level of Nav1.5 channels in both cell lines showed the 
expected results. The expression level appeared to be higher in 
MDA-MB-231 than in MCF-7 cells, in correlation with RhoA 
expression and activation pattern.
We found that RhoA controls the expression of Nav1.5 
that is recognized as the main type of functional VGSCs. 
The silencing of RhoA dramatically reduced the expression 
of Nav1.5 at its transcriptional level. Sustained (>48 h) treat-
ment with siRNA anti-RhoA markedly depressed sodium 
current. In addition, we found that RhoA silencing exerted a 
much stronger inhibitory effect on Nav1.5 than Nav1.7 (data 
not shown). These results indicated that RhoA plays a key role 
in sodium current, most probably via modulating the level of 
Nav1.5 channels. So far, this effect of RhoA on VGSC expres-
sion and function has not been reported in cancer cells or in 
non-tumor cells. Investigations in different types of normal 
and tumor cells remain to be done to clarify whether this effect 
of RhoA corresponds to physiological ubiquitous or tumor 
specific mechanism. Since RhoA is implicated in the forma-
tion of actin fibers, it would be of interest to know whether 
the suppression of RhoA by siRNA may lead to an interrupted 
integration of sodium channels into the cell membrane.
We noted that anti-Nav1.5 siRNA, not only markedly 
decreased sodium current by 70%, but also inhibited cell 
invasion and migration by 60-80%. Such results strongly 
support the notion that Nav1.5 is the main VGSC implicated 
in MDA-MB-231 cell invasiveness as suggested previously by 
Brackenbury et al and Gao et al (20,27).
Interestingly, a positive feed-back of Nav1.5 on RhoA 
was observed in this study. We found that inhibition by anti-
Nav1.5 siRNA led to a decrease in RhoA protein level in the 
cells. Surprisingly, the result of RT-PCR showed no change in 
the RhoA mRNA level. It suggests that Nav1.5 might affect 
the stability of the RhoA protein. Many post-transcriptional 
and post-translational events occur in cells such as phos-
phorylation, transglutamination, palmitoylation, AMPylation, 
isoprenylation, and ubiquitylation, and these modifications 
determine the distribution and life cycle of RhoA (28,29). 
Described mechanisms governing the stability of Rho proteins 
include phosphorylation of serine 188 on RhoA that protect 
against ubiquitin-mediated proteasomal degradation and gera-
nylgeranylation which facilitates proteasomal degradation of 
Rho (30,31).
Nav1.5-regulated RhoA protein level might be partially 
explained by a regulatory mechanism which involves sodium 
currents and intracellular calcium gradient. As a rule, Nav1.5-
mediated sodium currents influence the electrochemical 
gradient of calcium because sodium influx activates voltage-
dependent calcium channels and induces calcium entry. 
Indeed, the RhoA level was regulated by cytosolic calcium 
concentration. Rao et al demonstrated that the reduction of 
calcium concentration led to a decrease in Rho expression 
and the decrease in cytosolic calcium markedly destabilized 
the RhoA protein and accelerates its degradation (32). This 
allows assuming a likely accelerated RhoA degradation when 
blocking Nav1.5 function.
Therefore, a positive feed-back between RhoA and VGSCs 
would represent a crucial mechanism in oncogenesis. As 
RhoA is overexpressed and constitutively activated in various 
cancers including breast cancer (10,11), RhoA-mediated cancer 
invasiveness and metastasis could be partially via VGSC 
upregulation. Effectively it has been shown that in prostate 
cancer cells a significant increase in voltage-dependent chan-
nels was observed and found relative to the stimulation by EGF, 
a growth factor known for activating RhoA (33). Therefore, 
targeting RhoA signaling may be an interesting approach in 
cancer therapy.
Recently, the dominant VGSC was found to be an embry-
onic/neonatal splice variant (nNav1.5) consistent with the 
gene expression being ‘oncofoetal’. The molecular differences 
between the adult and neonatal isoforms of the VGSC/Nav1.5 
are 31 nucleotide differences, resulting in 7 amino acid differ-
ences (26). It was proposed that nNav1.5 is a novel marker 
with significant clinical potential for management of meta-
static breast cancer. However, the mechanisms responsible for 
the expression of VGSC especially the neonatal isoforms in 
metastatic cancers are not well elucidated. Therefore, further 
investigation of nNav1.5 expression and RhoA regulation 
seems to be of interest to better understand the regulation 
mechanisms between RhoA signaling and VGSC function and 
their implication in cancer malignancy.
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